- JP-listed companies
- KOBAYASHI PHARMACEUTICAL CO.,LTD.
KOBAYASHI PHARMACEUTICAL CO.,LTD.JP:4967
Market cap
¥431.6B
P/E ratio
21.2x
| Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | |
| Profit (loss) before income taxes | 18,853 | 19,666 | 20,056 | 18,755 | 19,802 | 22,572 | 25,304 | 26,804 | 26,635 | 27,636 | 27,950 | 27,559 |
| Depreciation | 2,622 | 2,677 | 2,641 | 2,587 | 2,112 | 2,926 | 2,964 | 3,731 | 3,837 | 3,973 | 4,360 | 4,929 |
| Impairment losses | 301 | 211 | 20 | 126 | 1,342 | 1,544 | 1,956 | 1,663 | 1,122 | 309 | 69 | 59 |
| Amortization of goodwill | 347 | 419 | 454 | 484 | 513 | 593 | 439 | 396 | 269 | 862 | 998 | 1,128 |
| Interest and dividend income | -473 | -567 | -552 | -638 | -539 | -657 | -715 | -985 | -747 | -588 | -579 | -763 |
| Interest expenses | 24 | 18 | 22 | 33 | 21 | 38 | 35 | 20 | 21 | 18 | 18 | 29 |
| Loss (gain) on sale of investment securities | -192 | -205 | -1,013 | -7 | -1,795 | -3 | - | -365 | -261 | -1 | -44 | -436 |
| Loss (gain) on valuation of investment securities | 408 | - | - | - | - | - | - | - | 9 | 67 | 133 | - |
| Loss (gain) on sale and retirement of non-current assets | 52 | 63 | 81 | 81 | 113 | 96 | 104 | 140 | 64 | 69 | 52 | 59 |
| Decrease (increase) in trade receivables | 213 | -2,322 | -907 | -282 | -11,045 | -2,969 | -3,367 | -1,426 | 1,588 | -1,523 | 8,296 | -3,781 |
| Decrease (increase) in inventories | -596 | 1,572 | -1,651 | -1,534 | 1,147 | -526 | -493 | -1,020 | 1,309 | -462 | -1,977 | -3,175 |
| Increase (decrease) in trade payables | -720 | -835 | 1,930 | 164 | 2,327 | 1,500 | 481 | -993 | -984 | 813 | 1,240 | -1,390 |
| Increase (decrease) in accounts payable - other | -2,355 | 405 | -701 | 1,882 | 5,955 | 4,057 | 320 | -785 | -3,194 | -177 | -1,002 | 1,918 |
| Increase (decrease) in accrued consumption taxes | 180 | 116 | 829 | -705 | 346 | 142 | -43 | -41 | 266 | -794 | 277 | -167 |
| Other, net | -293 | -213 | 388 | 1,318 | 481 | 312 | 849 | 334 | 1,501 | 193 | -431 | 16 |
| Subtotal | 16,501 | 19,981 | 21,098 | 20,059 | 19,294 | 27,990 | 27,241 | 26,912 | 31,160 | 30,247 | 39,363 | 25,986 |
| Interest and dividends received | 632 | 766 | 589 | 705 | 528 | 675 | 745 | 1,019 | 813 | 654 | 572 | 754 |
| Interest paid | -18 | -9 | -16 | -19 | -21 | -27 | -26 | -12 | -15 | -17 | -18 | -22 |
| Income taxes paid | -7,872 | -7,225 | -6,380 | -6,416 | -3,703 | -6,287 | -7,953 | -7,829 | -7,972 | -8,464 | -8,003 | -8,358 |
| Net cash provided by (used in) operating activities | 9,242 | 13,513 | 15,445 | 14,329 | 16,097 | 22,350 | 20,007 | 20,089 | 23,986 | 22,419 | 31,914 | 18,360 |
| Payments into time deposits | -42,540 | -64,010 | -67,500 | -83,000 | -63,870 | -52,455 | -55,084 | -52,836 | -51,271 | -49,285 | -47,567 | -45,132 |
| Proceeds from withdrawal of time deposits | 18,500 | 59,500 | 65,500 | 73,000 | 69,021 | 63,220 | 52,832 | 52,154 | 53,401 | 53,432 | 45,996 | 50,216 |
| Purchase of securities | -16,495 | - | - | - | - | - | - | - | - | - | -2,000 | -4,000 |
| Proceeds from sale and redemption of securities | 27,500 | 1,000 | 1,000 | - | - | - | - | - | 6,623 | 7,728 | 5,713 | 4,000 |
| Purchase of property, plant and equipment | -2,512 | -2,885 | -3,100 | -3,381 | -2,850 | -2,841 | -3,419 | -4,379 | -3,795 | -3,663 | -14,747 | -12,756 |
| Proceeds from sale of property, plant and equipment | 63 | 67 | 23 | 20 | 6 | 3 | 2 | 47 | 15 | 10 | 3 | 5 |
| Purchase of intangible assets | -363 | -459 | -578 | -666 | -635 | -364 | -282 | -425 | -354 | -522 | -1,482 | -813 |
| Purchase of investment securities | -14,696 | -338 | -21 | -23 | -18 | -1,064 | -27 | -23 | -6,620 | -182 | -19 | -220 |
| Proceeds from sale of investment securities | 192 | 10 | 56 | 338 | 315 | 715 | 641 | 1,084 | 705 | 402 | 45 | 531 |
| Purchase of shares of subsidiaries resulting in change in scope of consolidation | - | -300 | - | - | -2,469 | - | -2,461 | -1,054 | -11,355 | - | - | -11,176 |
| Other, net | -296 | -4 | -170 | -49 | - | -50 | - | -225 | -5 | -129 | -253 | -231 |
| Net cash provided by (used in) investing activities | -26,605 | -6,959 | -4,540 | -10,932 | -519 | 7,039 | -8,062 | -5,072 | -12,656 | 7,991 | -14,312 | -19,576 |
| Net increase (decrease) in short-term borrowings | - | 1 | 34 | 140 | 11 | -47 | 228 | -495 | -5 | -12 | -1 | - |
| Purchase of treasury shares | -1 | -2 | -1,501 | -8,109 | -8,054 | -5,068 | - | -8,014 | - | -3,943 | -14,056 | -12,000 |
| Dividends paid | -3,357 | -3,521 | -3,552 | -3,837 | -3,919 | -4,343 | -4,818 | -5,333 | -5,784 | -6,251 | -6,509 | -7,223 |
| Other, net | 1 | - | - | - | - | - | - | -738 | -227 | -169 | -191 | -239 |
| Net cash provided by (used in) financing activities | -3,729 | -3,809 | -5,155 | -10,199 | -11,922 | -9,162 | -4,285 | -14,581 | -6,019 | -10,377 | -20,759 | -19,463 |
| Effect of exchange rate change on cash and cash equivalents | 578 | 831 | 751 | -167 | -760 | 137 | -431 | -79 | -425 | 797 | 673 | 890 |
| Net increase (decrease) in cash and cash equivalents | -20,513 | 3,576 | 6,500 | -6,971 | 2,894 | 20,365 | 7,228 | 356 | 4,884 | 20,830 | -2,484 | -19,789 |
| Increase (decrease) in cash and cash equivalents resulting from accounting term alterations of subsidiaries | - | - | - | - | - | - | - | - | - | - | -22 | - |